This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, Tunisia, Turkey, UK.
The drug FERRIPROX contains one active pharmaceutical ingredient (API):
1
|
UNII
2BTY8KH53L - DEFERIPRONE
|
|
Deferiprone is a bidentate ligand which binds iron in a 3:1 molar ratio. Deferiprone monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| FERRIPROX Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| Ferriprox 100 mg/ml oral solution | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| V03AC02 | Deferiprone | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AC Iron chelating agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 11724C, 11747G, 5657R, 5658T, 6416Q, 9638G |
| BR | Câmara de Regulação do Mercado de Medicamentos | 508501401110313 |
| CA | Health Products and Food Branch | 02436523, 02436531, 02436558 |
| EE | Ravimiamet | 1199932, 1364150, 1364161, 1488270, 1488281 |
| ES | Centro de información online de medicamentos de la AEMPS | 99108001, 99108003 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 003687, 123020 |
| FR | Base de données publique des médicaments | 60508302, 65987486, 69694018 |
| GB | Medicines & Healthcare Products Regulatory Agency | 141888, 192699, 39639 |
| HK | Department of Health Drug Office | 49758, 58937, 62074 |
| IE | Health Products Regulatory Authority | 88262, 88263 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 6248, 7014, 8640 |
| IT | Agenzia del Farmaco | 034525042 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1028403, 1028404, 1028405, 1056125, 1056126, 1056127 |
| NL | Z-Index G-Standaard, PRK | 78425, 87106 |
| NZ | Medicines and Medical Devices Safety Authority | 13799, 13800, 19935 |
| PL | Rejestru Produktów Leczniczych | 100309697, 100309705, 100309711 |
| SG | Health Sciences Authority | 12083P, 13668P |
| TN | Direction de la Pharmacie et du Médicament | 1223011H, 1223012H |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699822090287, 8699822570291 |
| US | FDA, National Drug Code | 10122-104, 52609-0006, 52609-0007, 52609-4502 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.